» Articles » PMID: 8203357

Primary Focal Segmental Glomerulosclerosis: Clinical Course and Response to Therapy

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 1994 Jun 1
PMID 8203357
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Primary focal segmental glomerulosclerosis (FSGS) is a lesion associated with a poor prognosis and results in end-stage renal disease after 5 to 10 years. Based on past experience, many nephrologists have considered primary FSGS a lesion that is steroid resistant and therefore are reluctant to offer steroids as treatment. Recent data, however, have demonstrated that patients with primary FSGS have a response to steroid therapy that is considerably better than had been described. Thus, it may be that nephrologists have been more "steroid reluctant" than the lesion is steroid resistant. To better understand this issue we review the clinical course and response to therapy in patients with primary FSGS.

Citing Articles

Nephrotic and Non-Nephrotic Focal Segmental Glomerulosclerosis: Clinical Characteristics, Etiology, and Columbia Classification.

Figueiredo G, Yu L, Jorge L, Woronik V, Dias C Diagnostics (Basel). 2025; 15(2).

PMID: 39857004 PMC: 11763650. DOI: 10.3390/diagnostics15020120.


Renal survival and treatment of adult patients with Primary Focal Segmental glomerulosclerosis: A historical cohort study of the National Greek Registry.

Marinaki S, Kompotiatis P, Michelakis I, Stangou M, Papagianni A, Koukoulaki M PLoS One. 2024; 19(12):e0315124.

PMID: 39693288 PMC: 11654980. DOI: 10.1371/journal.pone.0315124.


Protective Effects of Astaxanthin against Oxidative Stress: Attenuation of TNF-α-Induced Oxidative Damage in SW480 Cells and Azoxymethane/Dextran Sulfate Sodium-Induced Colitis-Associated Cancer in C57BL/6 Mice.

Zhang H, Wang M, Zhou Y, Bao S, Wang F, Li C Mar Drugs. 2024; 22(10).

PMID: 39452878 PMC: 11509176. DOI: 10.3390/md22100469.


Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort.

Stamellou E, Nadal J, Hendry B, Mercer A, Bechtel-Walz W, Schiffer M Clin Kidney J. 2024; 17(7):sfae131.

PMID: 38989280 PMC: 11234294. DOI: 10.1093/ckj/sfae131.


Glucocorticoid- and pioglitazone-induced proteinuria reduction in experimental NS both correlate with glomerular ECM modulation.

Bhayana S, Dougherty J, Kamigaki Y, Agrawal S, Wijeratne S, Fitch J iScience. 2024; 27(1):108631.

PMID: 38188512 PMC: 10770536. DOI: 10.1016/j.isci.2023.108631.